Basic Information
Palonosetron Accord
Regulatory Information
EMEA/H/C/004129
May 26, 2016
March 31, 2016
8
July 19, 2024
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Palonosetron Accord is indicated in adults for: - the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, - the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Palonosetron Accord is indicated in paediatric patients 1 month of age and older for: - The prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Palonosetron Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Palonosetron Accord. For practical information about using Palonosetron Accord, patients should read the package leaflet or contact their doctor or pharmacist.